<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Autotaxin (ATX) is a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell motility-stimulating factor originally isolated from <z:hpo ids='HP_0002861'>melanoma</z:hpo> cell supernatants </plain></SENT>
<SENT sid="1" pm="."><plain>ATX is identical to lysophospholipase D, which produces a bioactive <z:chebi fb="23" ids="18059">lipid</z:chebi> mediator, <z:chebi fb="0" ids="52288">lysophosphatidic acid</z:chebi> (<z:chebi fb="8" ids="52288">LPA</z:chebi>), from <z:chebi fb="0" ids="11230">lysophosphatidylcholine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>ATX is overexpressed in various <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and ATX may stimulate <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> via <z:chebi fb="8" ids="52288">LPA</z:chebi> production </plain></SENT>
<SENT sid="3" pm="."><plain>The present study measured the serum ATX antigen levels in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> using a recently developed automated enzyme immunoassay </plain></SENT>
<SENT sid="4" pm="."><plain>The serum ATX antigen levels in patients with B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, especially follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), were higher than those in healthy subjects </plain></SENT>
<SENT sid="5" pm="."><plain>Serum ATX antigen levels in FL patients were associated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> burden and changed in parallel with the patients' clinical courses </plain></SENT>
<SENT sid="6" pm="."><plain>The serum ATX antigen levels were little affected by <z:mp ids='MP_0001845'>inflammation</z:mp>, unlike the soluble interleukin-2 receptor and beta2-microglobulin levels </plain></SENT>
<SENT sid="7" pm="."><plain>As expected, the plasma <z:chebi fb="8" ids="52288">LPA</z:chebi> levels in FL patients were correlated with the serum ATX antigen levels </plain></SENT>
<SENT sid="8" pm="."><plain>Given that leukaemic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells from FL patients expressed ATX, the shedding of ATX from <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells probably leads to the elevation of serum ATX antigen levels </plain></SENT>
<SENT sid="9" pm="."><plain>Our results suggest that the serum ATX antigen level may be a promising and novel marker for FL </plain></SENT>
</text></document>